These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22021821)

  • 1. High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH).
    Kenz S; Haas CS; Werth SC; Bohnet S; Brabant G
    Ann Oncol; 2011 Dec; 22(12):2696. PubMed ID: 22021821
    [No Abstract]   [Full Text] [Related]  

  • 2. [Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan].
    Schnaiter A; Hiddemann W
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2077-9. PubMed ID: 25268207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH.
    Menzi S; Jaramillo SD; Pfister S; Schefer H; Jehle AW
    Front Endocrinol (Lausanne); 2024; 15():1382066. PubMed ID: 38803472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
    Harbeck B; Lindner U; Haas CS
    Endocrine; 2016 Sep; 53(3):872-3. PubMed ID: 26961548
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer.
    Hainsworth JD; Workman R; Greco FA
    Cancer; 1983 Jan; 51(1):161-5. PubMed ID: 6295592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
    Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
    Mali P; Muduganti SR; Mujibur R; Murali N
    WMJ; 2015 Apr; 114(2):66-8. PubMed ID: 26756059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
    BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan.
    Carreño A; Hernández B; Mayoralas Á; Calle C
    Nefrologia; 2017; 37(5):558-559. PubMed ID: 28946972
    [No Abstract]   [Full Text] [Related]  

  • 10. Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
    Tantisattamo E; Ng RC
    Hawaii Med J; 2011 Jul; 70(7):139-43. PubMed ID: 21886301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer.
    Garrahy A; Hannon AM; Zia-Ul-Hussnain HM; Williams DJ; Thompson CJ
    Eur J Clin Pharmacol; 2018 Feb; 74(2):245-246. PubMed ID: 29147803
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
    Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
    Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA; Cranston IC
    BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.
    Graziani G; Cucchiari D; Aroldi A; Angelini C; Gaetani P; Selmi C
    J Neurol Neurosurg Psychiatry; 2012 May; 83(5):510-2. PubMed ID: 22323742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan: any evidence of efficacy in SIADH?
    Prescrire Int; 2010 Oct; 19(109):197-200. PubMed ID: 21180368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
    Sánchez Sobrino P; Fernández Catalina P; Lorenzo Solar M; Rego Iraeta A
    Med Clin (Barc); 2015 Aug; 145(3):138-9. PubMed ID: 25543222
    [No Abstract]   [Full Text] [Related]  

  • 20. [Tolvaptan in antidiuretic hormone secretion syndrome secondary to treatment with citalopram].
    Pinal-Fernández I; Segura-García A
    Rev Clin Esp; 2011 Oct; 211(9):491-2. PubMed ID: 21531406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.